| 1 |
Li B, Qian L, Pi L, Meng X. A therapeutic role of exosomal lncRNA H19 from adipose mesenchymal stem cells in cutaneous wound healing by triggering macrophage M2 polarization. Cytokine 2023;165:156175. [PMID: 36948039 DOI: 10.1016/j.cyto.2023.156175] [Reference Citation Analysis]
|
| 2 |
Cui Z, Du L, Wang J, Li Z, Xu J, Ou S, Li D, Li S, Hu H, Chen G, Wu Z. Overexpression of CENPL mRNA potentially regulated by miR-340-3p predicts the prognosis of pancreatic cancer patients. BMC Cancer 2022;22:1354. [PMID: 36572856 DOI: 10.1186/s12885-022-10450-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Qiao Z, Xing Y, Zhang Q, Tang Y, Feng R, Pang W. Tamoxifen resistance-related ceRNA network for breast cancer. Front Cell Dev Biol 2022;10:1023079. [PMID: 36506097 DOI: 10.3389/fcell.2022.1023079] [Reference Citation Analysis]
|
| 4 |
Zhang X, Luo M, Zhang J, Guo B, Singh S, Lin X, Xiong H, Ju S, Wang L, Zhou Y, Zhou J. The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers. Front Genet 2022;13:1005522. [DOI: 10.3389/fgene.2022.1005522] [Reference Citation Analysis]
|
| 5 |
Hashemi M, Moosavi MS, Abed HM, Dehghani M, Aalipour M, Heydari EA, Behroozaghdam M, Entezari M, Salimimoghadam S, Gunduz ES, Taheriazam A, Mirzaei S, Samarghandian S. Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy. Pharmacol Res 2022;184:106418. [PMID: 36038043 DOI: 10.1016/j.phrs.2022.106418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Garcia-padilla C, Lozano-velasco E, Muñoz-gallardo MDM, Castillo-casas JM, Caño-carrillo S, Martínez-amaro FJ, García-lópez V, Aránega A, Franco D, García-martínez V, López-sánchez C. LncRNA H19 Impairs Chemo and Radiotherapy in Tumorigenesis. IJMS 2022;23:8309. [DOI: 10.3390/ijms23158309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Singh D, Assaraf YG, Gacche RN. Long Non-coding RNA Mediated Drug Resistance in Breast Cancer. Drug Resistance Updates 2022. [DOI: 10.1016/j.drup.2022.100851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Yin X, Lin H, Lin L, Miao L, He J, Zhuo Z. LncRNAs and CircRNAs in cancer. MedComm 2022;3. [DOI: 10.1002/mco2.141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Ye P, Feng L, Shi S, Dong C. The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer. Cancers (Basel) 2022;14:2101. [PMID: 35565231 DOI: 10.3390/cancers14092101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Mahabady MK, Mirzaei S, Saebfar H, Gholami MH, Zabolian A, Hushmandi K, Hashemi F, Tajik F, Hashemi M, Kumar AP, Aref AR, Zarrabi A, Khan H, Hamblin MR, Nuri Ertas Y, Samarghandian S. Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity. J Cell Physiol 2022;237:2309-44. [PMID: 35437787 DOI: 10.1002/jcp.30751] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 11 |
Yardım-Akaydin S, Karahalil B, Nacak Baytas S. New therapy strategies in the management of breast cancer. Drug Discov Today 2022:S1359-6446(22)00124-6. [PMID: 35337961 DOI: 10.1016/j.drudis.2022.03.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 12 |
Chen Y, Li X, Xu J, Xiao H, Tang C, Liang W, Zhu X, Fang Y, Wang H, Shi J. Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/β-catenin signaling pathway. Bioengineered 2022;13:3526-36. [PMID: 35200072 DOI: 10.1080/21655979.2021.2018973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Xie W, Shu T, Peng H, Liu J, Li C, Wang M, Wu P, Liu Y. LncRNA H19 inhibits oxidative stress injury of cochlear hair cells by regulating miR-653-5p/SIRT1 axis. Acta Biochim Biophys Sin (Shanghai) 2022;54:332-9. [PMID: 35538041 DOI: 10.3724/abbs.2022018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 14 |
Wu B, Zhang Y, Yu Y, Zhong C, Lang Q, Liang Z, Lv C, Xu F, Tian Y. Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways. Front Cell Dev Biol 2021;9:796740. [PMID: 34977037 DOI: 10.3389/fcell.2021.796740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 15 |
Sun J, Zheng X, Wang B, Cai Y, Zheng L, Hu L, Lu X, Xie S, Zhang X, Liu H, Ye L. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells. Acta Biochim Biophys Sin (Shanghai) 2022;54:261-70. [PMID: 35130616 DOI: 10.3724/abbs.2021019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 16 |
Fu D, Ji Q, Wang C, Yu L, Yu R. Aloin decelerates the progression of hepatocellular carcinoma through circ_0011385/miR-149-5p/WT1 axis. Cell Cycle 2021;:1-18. [PMID: 34720052 DOI: 10.1080/15384101.2021.1988227] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Chang J, Zhang Y, Ye X, Guo H, Lu K, Liu Q, Guo Y. Long non-coding RNA (LncRNA) CASC9/microRNA(miR)-590-3p/sine oculis homeobox 1 (SIX1)/NF-κB axis promotes proliferation and migration in breast cancer. Bioengineered 2021;12:8709-23. [PMID: 34711117 DOI: 10.1080/21655979.2021.1977555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 18 |
Qu W, Wei X, Zhang H, Hou J. FOXD1-AS1 promotes malignant behaviours of prostate cancer cells via the miR-3167/YWHAZ axis. Andrologia 2021;:e14263. [PMID: 34674391 DOI: 10.1111/and.14263] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 19 |
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer Metastasis Rev 2021. [PMID: 34524579 DOI: 10.1007/s10555-021-09992-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 20 |
Yang J, Qi M, Fei X, Wang X, Wang K. LncRNA H19: A novel oncogene in multiple cancers. Int J Biol Sci 2021;17:3188-208. [PMID: 34421359 DOI: 10.7150/ijbs.62573] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 21 |
Ashrafizadeh M, Mirzaei S, Hashemi F, Zarrabi A, Zabolian A, Saleki H, Sharifzadeh SO, Soleymani L, Daneshi S, Hushmandi K, Khan H, Kumar AP, Aref AR, Samarghandian S. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomed Pharmacother 2021;141:111824. [PMID: 34175815 DOI: 10.1016/j.biopha.2021.111824] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 22 |
Venkatesh J, Wasson MD, Brown JM, Fernando W, Marcato P. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. Cancer Lett 2021;509:81-8. [PMID: 33848519 DOI: 10.1016/j.canlet.2021.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 23 |
Ren K, Yu Y, Wang X, Liu H, Zhao J. MiR-340-3p-HUS1 axis suppresses proliferation and migration in lung adenocarcinoma cells. Life Sci 2021;274:119330. [PMID: 33711383 DOI: 10.1016/j.lfs.2021.119330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Ghafouri-Fard S, Shoorei H, Bahroudi Z, Abak A, Taheri M. The role of H19 lncRNA in conferring chemoresistance in cancer cells. Biomed Pharmacother 2021;138:111447. [PMID: 33667788 DOI: 10.1016/j.biopha.2021.111447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Kim H, Ji HW, Kim HW, Yun SH, Park JE, Kim SJ. Ginsenoside Rg3 Prevents Oncogenic Long Noncoding RNA ATXN8OS from Inhibiting Tumor-Suppressive microRNA-424-5p in Breast Cancer Cells. Biomolecules 2021;11:118. [PMID: 33477683 DOI: 10.3390/biom11010118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 26 |
Yin X, Wang P, Yang T, Li G, Teng X, Huang W, Yu H. Identification of key modules and genes associated with breast cancer prognosis using WGCNA and ceRNA network analysis. Aging (Albany NY) 2020;13:2519-38. [PMID: 33318294 DOI: 10.18632/aging.202285] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 27 |
Zhong G, Lin Y, Wang X, Wang K, Liu J, Wei W. H19 Knockdown Suppresses Proliferation and Induces Apoptosis by Regulating miR-130a-3p/SATB1 in Breast Cancer Cells. Onco Targets Ther 2020;13:12501-13. [PMID: 33324070 DOI: 10.2147/OTT.S280142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
